In yesterday’s Wall Street session, Seelos Therapeutics Inc (NASDAQ:SEEL) shares traded at $0.12, up 0.41% from the previous session.
As of this writing, 2 analysts cover Seelos Therapeutics Inc (NASDAQ:SEEL). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $4.00, we find $4.00. Given the previous closing price of $0.12, this indicates a potential upside of 3233.33 percent. SEEL stock price is now -65.32% away from the 50-day moving average and -84.86% away from the 200-day moving average. The market capitalization of the company currently stands at $18.52M.
There are 1 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $4.00 as their price target over the next twelve months.
With the price target enhanced from $2.50 to $8, ROTH Capital Upgraded its rating from Neutral to Buy for Seelos Therapeutics Inc (NASDAQ: SEEL).
A total of 2.17% of the company’s stock is owned by insiders.
During the past 12 months, Seelos Therapeutics Inc has had a low of $0.12 and a high of $1.66. The fifty day moving average price for SEEL is $0.3578 and a two-hundred day moving average price translates $0.8188 for the stock.
The latest earnings results from Seelos Therapeutics Inc (NASDAQ: SEEL) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.22, missing analysts’ expectations of -$0.09 by -0.13. This compares to -$0.20 EPS in the same period last year. The net profit margin was -7096.85% and return on equity was -584.20% for SEEL.
Seelos Therapeutics Inc(SEEL) Company Profile
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson’s disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.